Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 6/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25607366 | 0.83 | CYP11B2 (0.56) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL24088755 | 0.80 | CYP11B2 (0.48) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL31676635 | 0.80 | CYP11B2 (0.48) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL22490765 | 0.80 | CYP11B2 (0.44) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL21392103 | 0.78 | CTPS1 (0.54) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL21392101 | 0.78 | CTPS1 (0.53) | METCYP11B2CYP11B1 | |
| SCHEMBL29489098 | 0.78 | CTPS1 (0.53) | METCYP11B2CYP11B1 | |
| SCHEMBL30415999 | 0.78 | CTPS1 (0.54) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL30987732 | 0.76 | ABL1 (0.44) | NPC1RAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL27272854 | 0.76 | ABL1 (0.44) | NPC1RAB9ASMN1; SMN2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-11505547-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2022-11-22 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3717465-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | NPC1 69/4885RAB9A 2440/4885SMN1; SMN2 2367/4885 |
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | NPC1 69/4885RAB9A 2440/4885SMN1; SMN2 2367/4885 |
| US-20250263407-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | NPC1 72/4885RAB9A 2248/4885SMN1; SMN2 1991/4885 |
| US-11505547-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | NPC1 69/4885RAB9A 2440/4885SMN1; SMN2 2367/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | NPC1 69/4885RAB9A 2440/4885SMN1; SMN2 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.